Sponsored

Imugene Enters into Licensing Agreement with City of Hope for Patents Covering onCARlyticsTM

Summary

  • Imugene Limited (ASX:IMU) and City of Hope have recently entered into a licensing agreement for the patents covering a novel combination immunotherapy, onCARlyticsTM.
  • onCARlyticsTM makes the treatment of solid tumours by CAR T drugs viable.
  • The Company expects the initiation of the onCARlyticsTM Phase 1 study in 2022.

Australia-based Imugene Limited (ASX:IMU) has added more bling to its existing product pipeline, enhancing its portfolio with a novel CD19 expressing oncolytic virus from City of Hope® to turn CAR T therapy against solid tumours. The Company has recently entered into a licensing agreement with City of Hope for the patents covering a novel combination immunotherapy, onCARlyticsTM (CF33-CD19).

Following the key update, Imugene shares rallied by over 4.5 per cent to AUD 0.345 as of 2:00 PM AEST.

Must Read: Success Story of Imugene Limited (ASX:IMU): Australia’s Newest AUD 1 Billion Company

onCARlyticsTM is a unique and effective combination immunotherapy utilising Imugene’s exclusively licensed CF33 oncolytic virus to deliver and present cell surface CD19 antigen promoting CD19 Chimeric Antigen Receptor (CAR) T cell anti-tumour responses against solid tumours.

Currently, CAR T cell therapy has limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen CD19. Interestingly, onCARlyticsTM makes the treatment of solid tumours by CAR T drugs viable.

Imugene expects the initiation of the onCARlyticsTM Phase 1 study in 2022, which will evaluate the safety and efficacy of CF33-CD19 in combination with CAR T therapy in patients with solid tumours. Besides, Phase 1 CF33 oncolytic virus studies, commencing shortly, are also expected to accelerate the development of onCARlyticsTM.

Developed at City of Hope

onCARlytics™ or an agent that identifies cancer cells for destruction of CAR T cells was developed at City of Hope. Led by Saul Priceman (PhD), City of Hope scientists combined two strong immunotherapies - CD19 CAR T cell therapy and Imugene’s CD19 oncolytic virus.  These therapies were combined with the goal of targeting and destroying solid tumours that are otherwise hard to treat with CAR T cell therapy alone.

Scientists at City of Hope genetically engineered an oncolytic virus to get into tumour cells and force production of CF33-CD19 on the cell surface. Then, the scientists were able to utilise CD19 directed CAR T cells to identify and attack these solid tumours. Recently, the preclinical research was published and featured on the front cover of the prominent journal, Science Translational Medicine.

As per Dr Priceman, City of Hope’s research shows that oncolytic viruses are a promising and powerful approach that can be strategically combined with CAR T cell therapy in order to effectively target solid tumours in patients.

Currently, CD19 CAR T cell therapy is approved by the U.S. FDA (Food and Drug Administration) to treat specific types of blood cancers, including acute lymphoblastic leukemia and B cell lymphomas. The new research may increase the use of CD19 CAR T therapy with CF33-CD19 for the treatment of patients with potentially any type of solid tumour.

Do Not Miss: Imugene Limited ends an action-packed Q1 2021 with robust cash balance

Four-Year Sponsored Research Agreement

Imugene has executed a four-year Sponsored Research Agreement with City of Hope and its research team led by Dr Priceman to further develop the cell therapy technology. Under the terms of the licence agreement, the Company will acquire the exclusive worldwide rights to develop as well as commercialise the patents encompassing the CF33-CD19.

Imugene has agreed to pay City of Hope license fees comprising an upfront cost, annual maintenance fees that are creditable against future royalty payments, performance-based consideration associated with the achievement of certain value inflection development milestones & commercial outcomes, net sales based on single-digit royalty payments, as well as sublicensing fees.

Good Read: Imugene (ASX:IMU) Continues to Develop B-Cell Vaccines and Oncolytic Virotherapy in 1H FY21

The Company notified that all upfront cash payments under the licence agreement will be funded through its current cash reserves.

All in all, the worldwide exclusive license to combine the oncolytic virus and cell therapy technology offers Imugene numerous partnering or collaboration opportunities for both approved and in-development CAR Ts.

Also Read: Here is Imugene’s latest update on anti-cancer therapies HER-Vaxx & CF33

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK